Agios Pharmaceuticals, Inc.

NasdaqGS:AGIO Stock Report

Market Cap: US$1.6b

Agios Pharmaceuticals Future Growth

Future criteria checks 2/6

Agios Pharmaceuticals is forecast to grow earnings and revenue by 34.3% and 55.5% per annum respectively. EPS is expected to grow by 35.5% per annum. Return on equity is forecast to be -34.7% in 3 years.

Key information

34.3%

Earnings growth rate

35.48%

EPS growth rate

Biotechs earnings growth23.8%
Revenue growth rate55.5%
Future return on equity-34.68%
Analyst coverage

Good

Last updated25 Dec 2025

Recent future growth updates

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Aug 04
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Recent updates

Agios Pharma Stock: A Buy After FDA Approves Aqvesme

Dec 24

Why Agios Pharmaceuticals' (NASDAQ:AGIO) Earnings Are Weaker Than They Seem

Feb 20
Why Agios Pharmaceuticals' (NASDAQ:AGIO) Earnings Are Weaker Than They Seem

Agios Pharmaceuticals: Liver Toxicity Issues May Threaten Thalassemia Approval (Rating Downgrade)

Feb 14
User avatar

Mitapivat May Launch In 2025 For Blood Disorders But Faces Regulatory And Competition Challenges

Mitapivat's launch in thalassemia and sickle cell markets promises revenue growth from new opportunities, leveraging positive Phase III data for adoption.

Agios Pharmaceuticals: Considering Risk/Reward Ahead Of FDA Decision

Jan 14

Agios Pharmaceuticals: A Long Overdue Follow Up

Dec 03

We're Not Very Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Rate

Sep 26
We're Not Very Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Rate

Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment

Aug 27

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Aug 04
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline

Jun 12

Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth

Jun 02
Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth

Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates

Feb 17
Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates

Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

Jan 16
Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 50%

Nov 09
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 50%

Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

Sep 26
Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?

May 08
Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?

Earnings and Revenue Growth Forecasts

NasdaqGS:AGIO - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027250-310-212-1499
12/31/2026109-398-252-19210
12/31/202546-420-456-60010
9/30/202545-401-424-410N/A
6/30/202541650-419-406N/A
3/31/202537666-404-401N/A
12/31/202436674-392-390N/A
9/30/202433674-330-329N/A
6/30/202431-365-325-307N/A
3/31/202429-353-319-301N/A
12/31/202327-352-315-296N/A
9/30/202324-220-308-290N/A
6/30/202320-210-300-299N/A
3/31/202319-218-309-307N/A
12/31/202214-232-314-309N/A
9/30/202210-367-337-327N/A
6/30/20226-369-350-341N/A
3/31/20221-360-392-384N/A
12/31/2021N/A-357-413-407N/A
9/30/2021N/A-342-374-373N/A
6/30/2021N/A-337-363-356N/A
3/31/2021N/A-336-317-306N/A
12/31/2020N/A-329-305-291N/A
9/30/202035-347-355-335N/A
6/30/202061-374-370-352N/A
3/31/202088-402-387-373N/A
12/31/2019N/A-301-383-371N/A
9/30/2019112-401-358-351N/A
6/30/2019102-389N/A-329N/A
3/31/2019116-348N/A-309N/A
12/31/201894-346N/A-304N/A
9/30/201874-343N/A-305N/A
6/30/201870-325N/A-319N/A
3/31/201841-339N/A-310N/A
12/31/201743-315N/A-285N/A
9/30/201756-283N/A-262N/A
6/30/201753-269N/A-233N/A
3/31/201749-241N/A-17N/A
12/31/201670-198N/A39N/A
9/30/201653-183N/A59N/A
6/30/201650-160N/A83N/A
3/31/201656-136N/A-70N/A
12/31/201559-118N/A-77N/A
9/30/201568-104N/A-54N/A
6/30/201596-60N/A-53N/A
3/31/201591-46N/A-58N/A
12/31/201465-54N/A-59N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AGIO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AGIO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AGIO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AGIO's revenue (55.5% per year) is forecast to grow faster than the US market (10.7% per year).

High Growth Revenue: AGIO's revenue (55.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: AGIO is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/28 02:01
End of Day Share Price 2025/12/26 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Agios Pharmaceuticals, Inc. is covered by 31 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
George FarmerBMO Capital Markets Equity Research
Alec StranahanBofA Global Research